此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

MS and Health Cohort (MS-Health)

Disability Progression in Multiple Sclerosis: Determinants, Pathophysiology, and Global Health Impact

This study aims to identify clinical, biological, imaging, and environmental factors that predict the progression and severity of Multiple Sclerosis (MS). We will establish a prospective, highly phenotyped cohort of patients diagnosed with MS according to the 2024 criteria, regardless of disease form or stage.

We hypothesize that combining neurological, vascular, metabolic, neuropsychological, environmental, and imaging data (from the central nervous system and the eye) will improve the identification of markers associated with MS progression. This integrative approach will help clarify the respective roles of inflammation, vascular dysfunction, myelin repair, and neurodegeneration in disability accumulation.

The study will also evaluate the impact of MS, disability, and treatments on patients' physical, mental, and social health, as defined by the World Health Organization (WHO). These results are expected to support personalized patient management and identify modifiable risk factors to reduce disability and inform future therapeutic strategies.

The primary objective is to identify factors that worsen neurological disability in MS patients, including disease-related, comorbidity, and environmental factors. The main outcome measure is time to confirmed disability accumulation (CDA), defined as an increase in the EDSS (Expanded Disability Status Scale) score confirmed after at least 3 months.

This single-center, 5-year prospective cohort study will be conducted at Hôpital Fondation Adolphe de Rothschild (Paris, France), with annual visits. A linkage with national health data (SNDS) will be established for both MS patients and a matched control group (5:1 ratio).

Additional research procedures include:

Ophthalmologic exams (OCT, angio-OCT, fundus photography, pupillometry) at baseline, year 1, 3, and 5.

Brain MRI with additional non-contrast research sequences (annual).

Clinical assessments including arterial stiffness and hearing tests.

Blood sampling (up to 40 mL) for biomarker analyses and long-term biobanking (25 years).

Lumbar puncture if clinically indicated at baseline (with extra samples for research).

Physical activity and circadian rhythm monitoring using a wrist accelerometer for 9 consecutive days.

Standardized questionnaires assessing quality of life, education, and social/professional impact.

Inclusion criteria:

Age ≥ 18 years

Diagnosis of MS according to 2024 criteria

研究概览

地位

尚未招聘

研究类型

观察性的

注册 (估计的)

2000

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

取样方法

非概率样本

研究人群

This is a monocentric cohort study conducted at the Fondation Rothschild Hospital, Paris, France (75019). The study will include adult patients with multiple sclerosis diagnosed according to the 2024 diagnostic criteria for multiple sclerosis who are followed at the institution.

描述

Inclusion Criteria:

  • Age ≥ 18 years.
  • Multiple sclerosis defined according to the 2024 criteria.
  • Participant affiliated with or beneficiary of a social security system, Universal - -- Health Coverage (CMU), or any equivalent healthcare coverage scheme.
  • Written informed consent.

Exclusion Criteria:

  • Pregnant or breastfeeding women.
  • Progressive disease with a life expectancy of less than one year.
  • Inability to undergo MRI
  • Person refusing to be informed of any clinically significant finding concerning their health discovered during participation in the study.
  • Patient impairment making participation in the study or understanding of the - information provided difficult or impossible.
  • Person under legal protection measures (guardianship, curatorship, or judicial protection).
  • Person deprived of liberty by judicial or administrative decision.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Confirmed disability accumulation (CDA)
大体时间:5 years
The primary endpoint will be time to confirmed disability accumulation. Confirmed disability accumulation (CDA) will be defined as an increase in the Expanded Disability Status Scale (EDSS) score of ≥1.5 points if the previous EDSS score was 0; ≥1.0 point if the previous EDSS score ranged from 1.0 to 5.5; and ≥0.5 point if the previous EDSS score was greater than 5.5 (19). The increase must be confirmed after a minimum of 3 months. Each patient may experience one or several episodes of neurological disability worsening during follow-up.
5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月11日

初级完成 (估计的)

2034年6月1日

研究完成 (估计的)

2034年6月1日

研究注册日期

首次提交

2026年6月9日

首先提交符合 QC 标准的

2026年6月9日

首次发布 (实际的)

2026年6月12日

研究记录更新

最后更新发布 (实际的)

2026年6月12日

上次提交的符合 QC 标准的更新

2026年6月9日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅